Gastrointestinal Cancer | Topics

FDA Grants Priority Review to BLA for Retifanlimab as Possible Treatment for SCAC
January 22, 2021

The BLA submission is based on data observed in the phase 2 POD1UM-202 trial of retifanlimab in previously treated patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who had progressed on, or were intolerant of, standard platinum-based chemotherapy.

FDA Grants Priority Review to 2 sBLAs for Nivolumab in the Treatment of Cancers of the Gastrointestinal Tract
January 20, 2021

Bristol Myers Squibb announced that nivolumab has been granted priority review for indications in both the first-line and adjuvant treatment settings as therapy for gastrointestinal cancers.

Lenvatinib Effective as First Line Therapy for Patients with Hepatocellular Carcinoma
January 17, 2021

Lenvatinib monotherapy was an effective first-line therapy for patients with unresectable hepatocellular carcinoma, according to data from a retrospective, real-world analysis.